Respiratory Virus Surveillance Among Children with Acute Respiratory Illnesses — New Vaccine Surveillance Network, United States, 2016–2021

• DOI: 10.15585/mmwr.mm7140a1
• Publication Date: 2022-10-06T11:16:56Z
• Authors: Ariana Perez; Joana Y. Lively; Aaron Curns; Geoffrey A. Weinberg; Natasha B. Halasa; Mary Allen Staat; Peter G. Szilagyi; Laura S. Stewart; Monica M. McNeal; Benjamin Clopper; Yingtao Zhou; Brett L. Whitaker; Elizabeth LeMasters; Elizabeth Harker; Janet A. Englund; Eileen J. Klein; Rangaraj Selvarangan; Christopher J. Ha...; Julie A. Boom; Leila C. Sahni; Marian G. Michaels; John V. Williams; Gayle E. Langley; Susan I. Gerber; Angela Campbell; Aron J. Hall; Brian Rha; Meredith McMorrow; ; ; Bonnie Strelitz; Kirsten Lacombe; Mary Moffatt; Jennifer Schuster; Chelsea Rohlfs; Miranda Howard; Yesenia Romero; James Chappell; Pedro A. Piedra; Vasanthi Avadhanula; Wende Fregoe; Christina Albertin; Robert H. Hickey; Judith M Martin
• Keywords: Rhinovirus; Human Parainfluenza Virus

The New Vaccine Surveillance Network (NVSN) is a prospective, active, population-based surveillance platform that enrolls children with acute respiratory illnesses (ARIs) at seven pediatric medical centers. ARIs are caused by viruses including influenza virus, syncytial virus (RSV), human metapneumovirus (HMPV), parainfluenza (HPIVs), and most recently SARS-CoV-2 (the causes COVID-19), which result in morbidity among infants young (1-6). NVSN estimates the incidence of pathogen-specific collects clinical data (e.g., underlying conditions vaccination status) to assess risk factors for severe disease calculate COVID-19 vaccine effectiveness. Current inpatient (i.e., hospital) began 2015, expanded emergency departments (EDs) 2016, outpatient clinics 2018. This report describes demographic characteristics enrolled who received care these settings, yearly circulation influenza, RSV, HMPV, HPIV1-3, adenovirus, rhinovirus enterovirus (RV/EV),* during December 2016-August 2021. Among 90,085 eligible infants, children, adolescents (children) aged <18 years